These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
188 related items for PubMed ID: 23196204
21. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B, Pentavac Study Group. Vaccine; 2004 Mar 29; 22(11-12):1415-22. PubMed ID: 15063564 [Abstract] [Full Text] [Related]
22. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Vaccine; 2006 May 29; 24(22):4727-36. PubMed ID: 16616973 [Abstract] [Full Text] [Related]
23. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants. Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, Lattanzi M. Hum Vaccin Immunother; 2013 Sep 29; 9(9):1903-9. PubMed ID: 23783081 [Abstract] [Full Text] [Related]
24. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, Rofiq A, Prijanto M, Julitasari, Yela U, Herzog C, Cryz SJ. Vaccine; 2006 Mar 10; 24(11):1776-85. PubMed ID: 16303216 [Abstract] [Full Text] [Related]
25. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine. Gentile A, Umido V, Czerniuk P, Nacul J, Seigelchifer M, Hilbert AK, Yela U, Herzog C, Aeberhard U, Spyr C. Int J Infect Dis; 2011 Jan 10; 15(1):e24-9. PubMed ID: 21093342 [Abstract] [Full Text] [Related]
26. The effect of reconstitution of an Haemophilus influenzae type b-tentanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up. Hoppenbrouwers K, Roelants M, Ethevenaux C, Vandermeulen C, Knops J, Desmyter J. Vaccine; 1999 Jun 04; 17(20-21):2588-98. PubMed ID: 10418907 [Abstract] [Full Text] [Related]
27. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. Nolan T, Hogg G, Darcy MA, Skeljo M, Carlin J, Boslego J. Vaccine; 2001 Feb 28; 19(15-16):2127-37. PubMed ID: 11228385 [Abstract] [Full Text] [Related]
28. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E. Vaccine; 2011 Feb 24; 29(10):1913-20. PubMed ID: 21219984 [Abstract] [Full Text] [Related]
29. A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6-14 weeks. Sharma H, Yadav S, Patil V, Chacko B, Kapre S, Jadhav S, Ravetkar S, Bahl S, Parekh S, Chakravarty A, Ashtagi G, Prasath A. Vaccine; 2011 Nov 08; 29(48):8773-9. PubMed ID: 21968445 [Abstract] [Full Text] [Related]
33. A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine. Dalvi S, Kulkarni PS, Phadke MA, More SS, Lalwani SK, Jain D, Manglani M, Garg BS, Doibale MK, Deshmukh CT, SIIL DTwP + HepB Hib Author Group. Hum Vaccin Immunother; 2015 Nov 08; 11(4):901-7. PubMed ID: 25933183 [Abstract] [Full Text] [Related]
34. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization. Li G, Zhang H, Zhou W, Ye Q, Li F, Wang H, Hou Q, Xu Y, Ma X, Tan Y, Wang L, Li Y, Li H, Meng F, Liang Q, Liu A, Qin C, Wei W, Liu J, Ruan C, Tao W, Zhang S, Zheng H, Zhu F. Vaccine; 2010 Jun 07; 28(25):4215-23. PubMed ID: 20399240 [Abstract] [Full Text] [Related]
35. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months. Riedemann S, Reinhardt G, Jara J, Rios R, Wenzel MS, Willems P, Bock HL. Int J Infect Dis; 2002 Sep 07; 6(3):215-22. PubMed ID: 12718838 [Abstract] [Full Text] [Related]
36. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Gimenez-Sanchez F, Kieninger DM, Kueper K, Martinon-Torres F, Bernaola E, Diez-Domingo J, Steul K, Juergens C, Gurtman A, Giardina P, Liang JZ, Gruber WC, Emini EA, Scott DA, 501 and 006 study groups. Vaccine; 2011 Aug 11; 29(35):6042-8. PubMed ID: 21704105 [Abstract] [Full Text] [Related]
38. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B, Pentavac study group. Vaccine; 2004 Mar 29; 22(11-12):1406-14. PubMed ID: 15063563 [Abstract] [Full Text] [Related]